Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 105 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. SL-172154 is in an ongoing Phase I clinical trial for the treatment of patients with ovarian cancer. The company is also evaluating SL-172154 in an ongoing Phase I clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia (AML), and higher-risk myelodysplastic syndromes (HR-MDS). The firm is also advancing a Gamma Delta T Cell Engager, GADLEN platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.